Comparative In Vitro Activities of Meropenem in Combination with Colistin, Levofloxacin, or Chloramphenicol Against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis.

[1]  F. Compain,et al.  In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. , 2018, Journal of medical microbiology.

[2]  N. nørskov-lauritsen,et al.  Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. , 2017, Journal of medical microbiology.

[3]  E. R. Rodrigues,et al.  Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis , 2016, Epidemiology and Infection.

[4]  S. Verhulst,et al.  Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease , 2016, The American journal of case reports.

[5]  J. Turton,et al.  Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  A. Peleg,et al.  Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies , 2015, Seminars in Respiratory and Critical Care Medicine.

[7]  M. Landini,et al.  In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. , 2014, The Journal of antimicrobial chemotherapy.

[8]  M. Skov,et al.  Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  P. Vandamme,et al.  Identification and distribution of Achromobacter species in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  J. Elborn,et al.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  S. Mishra,et al.  Miscellaneous Gram‐Negative Bacteria , 2012 .

[12]  M. Gonullu,et al.  Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans , 2012, Scandinavian journal of infectious diseases.

[13]  M. Almuzara,et al.  Achromobacter xylosoxidans: An Emerging Pathogen Carrying Different Elements Involved in Horizontal Genetic Transfer , 2012, Current Microbiology.

[14]  R. Albano,et al.  Achromobacter xylosoxidans: Characterization of Strains in Brazilian Cystic Fibrosis Patients , 2011, Journal of Clinical Microbiology.

[15]  V. Raia,et al.  Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[16]  B. Özbek,et al.  Postantibiotic Effects of Tigecycline, Colistin Sulfate, and Levofloxacin Alone or Tigecycline-Colistin Sulfate and Tigecycline-Levofloxacin Combinations against Acinetobacter baumannii , 2010, Chemotherapy.

[17]  G. Drusano,et al.  The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression , 2010, Antimicrobial Agents and Chemotherapy.

[18]  M. Almuzara,et al.  In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. , 2010, International journal of antimicrobial agents.

[19]  S. Leonardi,et al.  Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[20]  M. Vaneechoutte,et al.  Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[21]  Ronald N. Jones,et al.  Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. , 2005, International journal of antimicrobial agents.

[22]  R. Gibson,et al.  Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[23]  Tim Tolker-Nielsen,et al.  Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. , 2003, Current opinion in biotechnology.

[24]  L. Saiman,et al.  Identification and Antimicrobial Susceptibility ofAlcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis , 2001, Journal of Clinical Microbiology.

[25]  D. Nix,et al.  In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. , 2001, Diagnostic microbiology and infectious disease.

[26]  C. Chenoweth,et al.  Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  K. Rolston,et al.  The in-vitro susceptibility of Alcatigenes deni-trificans subsp.xylosoxidans to40 anti-microbial agents , 1990 .

[28]  R. Dessau,et al.  Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. , 1988, The Journal of hospital infection.

[29]  J. Klastersky,et al.  Synergistic combinations of antibiotics in gram-negative bacillary infections. , 1982, Reviews of infectious diseases.

[30]  W Satterlee,et al.  Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. , 1971, The New England journal of medicine.